BIO 2019

2019 to be the strongest dealmaking year of the last decade? Syneos reports

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Who_I_am)
(Image: Getty/Who_I_am)

Related tags: Syneos Health

Last year saw heightened market volatility, marked by international trade disputes, regulatory unrest, and a general feeling of uncertainty – but 2019 is off to a strong start with several multi-billion dollar deals.

Biopharma stock indexes experienced significant corrections in 2018, with high valuations quickly followed by sudden dips. Still, moving into the new year, M&A dealmaking jumped out of the gate with several multi-billion dollar deals in early 2019, according to Syneos.

The company will be presenting the Dealmakers' Intentions: 2019 Market Outlook report during BIO International next week in Philadelphia, PA. The survey, in its 11th​ year, included responses from more than 150 industry executives and business development professionals.

“Dealmaking in the life sciences industry got off to a strong start in Q1 2019, despite a steep market decline in the last quarter of 2018 and a government shutdown,”​ said Neel Patel, senior managing director, Syneos Health Consulting and author of the 2019 Dealmakers’ Intentions Study. 

Consequently, Patel told us: "2019 is on a path to be one of the strongest dealmaking years of the last decade."

At the BIO Super Session, Patel will be moderating the conversation, with panelists from Wells Fargo, Boston Pharmaceuticals, Eli Lilly and Company, and Roche, among others.

The discussion will set its sights to the next 12 months and address biopharmaceutical dealmakers’ intentions around licensing and acquisitions. It will also identify the areas of greatest opportunity for both buyers and sellers.

“For the first time, this year,” ​Patel added, “the survey also assessed company interest specifically in orphan drug opportunities, both in terms of the overall level of interest among dealmakers and by therapeutic area.”

The report, not currently released, also will cover “the top 10 hottest areas for licensing.”

Patel said these include, “technologies that have started to gain in prominence, shed light on the therapeutic areas that have fallen in and out of favor and reveal the next hot spot with commercial value.”

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us


View more